Martin Dietrich, MD, PhD

Wade Iams, MD, says the guidance has changed on what to do when a ROS1 result lands after chemoimmunotherapy has already started.

Wade Iams, MD, says adding RNA-based next-generation sequencing (NGS) to DNA-based NGS identifies about 15% more patients with actionable fusions, and urges clinicians to confirm whether the panel they ordered includes RNA at all, since the report rarely makes that obvious.

Trilaciclib protects bone marrow before SCLC chemotherapy, sharply reducing neutropenia, anemia, and thrombocytopenia, improving fatigue and keeping treatment on schedule without weakening tumor kill.

Trilaciclib reshapes SCLC supportive care by protecting bone marrow from chemo, reducing anemia and thrombocytopenia, and improving treatment tolerance and quality of life.

Explore innovative strategies in small cell lung cancer treatment, focusing on bone marrow protection to enhance patient outcomes and treatment durability.

Martin F. Dietrich, MD, PhD, discusses the use of the CDK4/6 inhibitor trilaciclib to address myelosuppression associated with chemotherapy in small cell lung cancer.

Martin Dietrich, MD, PhD, discusses the National Comprehensive Cancer Network guidelines for using MET inhibitors in patients with non–small cell lung cancer and their impact on sequencing therapies.

Martin Dietrich, MD, PhD, discusses the role MET alterations play as oncogenic drivers of non–small cell lung cancer.